Table 4.
Summary of Anticancer Activity (Safety Population)
| Response | Cohort A KRAS-mt NSCLC (N = 25) n (%) |
Cohort B Squamous NSCLC (N = 25) n (%) |
||
|---|---|---|---|---|
| n (%) | 95% CIa | n (%) | 95% CIa | |
| Best overall response | ||||
| CR | 0 | NA | 0 | NA |
| PR | 6 (24.0) | 9.4–45.1 | 2 (8.0) | 1.0–26.0 |
| Stable disease | 8 (32.0) | 15.0–53.5 | 14 (56.0) | 34.9–75.6 |
| PD | 5 (20.0) | 6.8–40.7 | 7 (28.0) | 12.1–49.4 |
| Nonevaluable | 6 (24.0) | 9.4–45.1 | 2 (8.0) | 1.0–26.0 |
| Overall response rate (CR + PR) | 6 (24.0) | 9.4–45.1 | 2 (8.0) | 1.0–26.0 |
| Disease control rate (CR + PR + stable disease) | 14 (56.0) | 34.9–75.6 | 16 (64.0) | 42.5–82.0 |
| PFS, median mo (95% CI) | 7.6 (1.6–NE) | 3.3 (1.4–5.2) | ||
| OS, median mo (95% CI) | 27.8 (9.9–NE) | 6.0 (3.7–13.1) | ||
CI, confidence interval; CR, complete response; KRAS-mt, KRAS-mutant; n, number of subjects in the specified category; N, number of subjects in safety population; NA, not applicable; NE, not estimable; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response.
a
CIs were based on the Clopper-Pearson method.